Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLEURAM study of ramucirumab + docetaxel in previously treated NSCLC with malignant pleural effusion
jRCTs071190013Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ramucirumab and docetaxel in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Primary endpoint: Pleural effusion control rate at 8 weeks. Started Oct 2019; status: completed.
02
Drugs
ramucirumabdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs071190013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071190013.